Industry News

GM Mosquito Release Commences in Grand Cayman
NeuroMetrix, Inc. today reported continued strong media attention focusing on the company's innovative Quell ® Wearable Pain Relief Technology™. Forbes– Can this wearable device really zap away chronic pain? Huffington Post– Wearables: When“ Too Good to Be True” Is No Longer True Wareable– Meet the wearables tackling pain relief Techlicious– Review of the Quell Wearable Pain Relief Device The Financial Exchange– Interview with Dr."/>
NeuroMetrix Reports Recent Media Coverage for Quell
Medical Services is moving its headquarters from Ivyland to an 80,000- square-foot space in Fort Washington to accommodate a continuing expansion, the company said in a release on Thursday. Ashfield, a unit of UDG Healthcare PLC, is moving to the new location following the growth of its workforce to 1500 members from 120 in 2007, the company said. The Fort Washington space is 60 percent larger than the previous location."/>
BRIEF: Medical outsourcing firm Ashfield moving to bigger offices in Fort Washington [The Philadelphia Inquirer]
Biostage, Inc. a biotechnology company developing bioengineered organ implants for life-threatening conditions of the esophagus, trachea and bronchus, will host a conference call on Thursday, Aug 11th, 2016 at 9:00 am ET to review its Q2 operational progress and financials. Biostage will announce its Q2 results and update pre-market that day. About Biostage, Inc.: www.biostage.com Biostage is a biotechnology company developing..."/>
Bioengineered Organ Implant Developer Biostage to Host Q2 Update Call Thursday, August 11th at 9:00 am ET
RenovaCare, Inc.,, the developer of novel medical grade liquid spray devices and patented CellMistTM and SkinGunTM technologies*, released a revolutionary' before and after' video that highlights the transformative treatment of severe burns by spraying a patient's own stem cells on the affected area to rapidly heal wounds. RenovaCare, Inc.,, the developer of novel medical grade liquid spray devices and patented CellMist (TM) and SkinGun (TM) technologies*, released a..."/>
Watch Remarkable 'Before-After' Patient Recovery Using RenovaCare SkinGun™
Baxter International Inc. is committed to enhancing the safety of medication preparation, and today announced the DoseEdge Pharmacy Workflow Manager has alerted clinicians to more than three million potential medication preparation errors..."/>
Baxter's DoseEdge Pharmacy System Identifies Potential Medication Errors For Clinicians Prior to Patient Administration
Agilent Technologies Inc. today announced that scientists using the company's comparative genomic hybridization technology have shown that cancer cell lines, which are broadly used in all aspects of biomedical research, may have vast differences in their genetic makeup, even when grown in the same batch. As a result, the scientists have recommended that cell culture banks use advanced genomic technologies, such as array CGH, to ensure the consistency of the..."/>
Agilent Technologies Array CGH Platform Assures Quality of Cancer Cell Lines Used in Biomedical Research
Auxilio, Inc., a leading provider of Managed Print Services and IT Security for the healthcare industry, today announces the roll out of its new MPS methodology to include a NO PRINT strategy at AHRMM16 Conference, to held on August 1-2, 2016 at the San Diego Convention Center. AHRMM, Association for Healthcare Resource& Materials Management, is an organization advancing the healthcare supply chain. " Our Company expects the news of a Managed Print Service..."/>
Auxilio, Inc. Announces Managed "NO PRINT" Services Poised to Be News at AHRMM16
Adaptimmune Therapeutics plc, a leader in T-cell therapy to treat cancer, today announced that the European Medicines Agency has granted access to its newly-established Priority Medicines regulatory initiative for the company’ s SPEAR ® T-cell therapy targeting NY-ESO for the treatment of HLA-A0201, HLA-A0205, or HLA-A0206 allele positive patients with inoperable or metastatic synovial sarcoma who have received prior..."/>
Adaptimmune Receives Access to Priority Medicines (PRIME) Regulatory Support for its SPEAR® T-cell Therapy Targeting NY-ESO for Treatment of Soft Tissue Sarcoma
Juno Therapeutics Inc.. Investors who purchased or otherwise acquired shares between June 4, 2016 and July 7, 2016 are encouraged to contact the firm in advance of the September 12, 2016 lead plaintiff motion deadline. If you are a shareholder who suffered a loss during the Class Period, click here to participate."/>
SHAREHOLDER NOTICE: Goldberg Law PC Announces Securities Class Action Lawsuit Against Juno Therapeutics Inc. And Encourages Investors with Losses to Contact the Firm
Agilent Technologies Inc. today announced that scientists using the company’ s comparative genomic hybridization technology have shown that cancer cell lines, which are broadly used in all aspects of biomedical research, may have vast differences in their genetic makeup, even when grown in the same batch. As a result, the scientists have recommended that cell culture banks use advanced genomic technologies, such as array CGH, to ensure the consistency of..."/>
Agilent Technologies Array CGH Platform Assures Quality of Cancer Cell Lines Used in Biomedical Research
Neovasc Inc.. Investors who purchased or otherwise acquired shares between January 26, 2015 and May 19, 2016 are encouraged to contact the firm in advance of the August 5, 2016 lead plaintiff motion deadline.. If you are a shareholder who suffered a loss during the Class Period, click here to participate."/>
SHAREHOLDER NOTICE: Goldberg Law PC Announces Securities Class Action Lawsuit against Neovasc Inc. and Encourages Investors with Losses to Contact the Firm
Medical Facilities Corporation will release its 2016 second quarter financial results prior to markets opening on Thursday, August 11, 2016. Following the release, management will host a conference call at 8:30 a.m. ET to review the financial results. All interested parties are invited to participate. Please dial 647-427-7450 or 1-888-231-8191 15 minutes prior to the call to secure a line."/>
Notice of Medical Facilities Corporation's 2016 Second Quarter Financial Results Conference Call and Webcast
Navidea Biopharmaceuticals, Inc. today announced that the Company will report its financial results for the second quarter of 2016, on Thursday, August 4, 2016 prior to a conference call with the investment community scheduled at 8:30 a.m. ET. Investors and the public are invited to access the live audio webcast through the link below."/>
Navidea Biopharmaceuticals to Announce Second Quarter 2016 Financial Results on August 4, 2016
athenahealth, Inc., a leading provider of cloud-based services and mobile applications for medical groups and health systems, today announced its Merit-Based Incentive Payment System Guarantee, which aims to shield healthcare providers and practices from downward payment adjustments under the proposed Medicare reimbursement program of the same name. The guarantee comes months ahead of the Centers for Medicare and Medicaid Services’..."/>
UPDATE -- athenahealth Announces Industry’s First MIPS Guarantee
Boston Scientific Corp. shares jumped on positive earnings news Thursday morning, as the maker of heart and vascular medical devices reported rising income and fresh progress in resolving thousands product-liability lawsuits against the company. The medical device maker, which employs about 7,300 people in the Twin Cities, boosted its earnings outlook for remainder of 2016 as its adjusted net income in the second quarter climbed 27 percent. Boston Scientific..."/>
Boston Scientific posts 27 percent net income jump in second quarter [Star Tribune (Minneapolis)]
Pfizer’ s oncology pipeline could enhance therapeutic benefit in patients. NEW YORK& CLEVELAND---- Pfizer Inc. and Western Oncolytics announced today that they have entered into a development collaboration, license and option agreement to advance Western Oncolytics’ novel oncolytic vaccinia virus, WO-12."/>
Pfizer and Western Oncolytics Announce Immuno-Oncology Research Collaboration to Investigate Novel Oncolytic Virus Technology
LivaNova PLC, a market-leading medical technology and innovation company, today announced that Andrea L. Saia has been elected to its board of directors as a non-executive director.. Saia brings considerable board and healthcare credentials to LivaNova following 11 years with Novartis AG as President and CEO of their CIBAVision subsidiary and as global head of their Vision Care Division. She currently serves on the board of Align Technologies and served..."/>
LivaNova PLC Names Andrea L. Saia to its Board of Directors
Allergan plc's generics business by Israeli generics specialist Teva Pharmaceutical Industries Ltd., the companies said. With the acceptance of the proposed consent order, Teva has satisfied the regulatory approval requirements under the purchase agreement to complete the acquisition of Actavis Generics."/>
US FTC Clears Teva’s USD 40.5bn Acquisition of Allergan’s Generics Business
Galmed Pharmaceuticals revealed on Thursday that it has entered into a license agreement in Korea for an exclusive, royalty-bearing license for the commercialisation of Aramchol, with an option to manufacture, for the treatment of fatty liver indications, including nonalcoholic steatohepatitis in partnership with SAMIL Pharm Co Ltd.. Pursuant to the license agreement, Samil will pay Galmed an up-front fee of approximately USD2.0m."/>
Galmed Pharmaceuticals partners with SAMIL Pharm for the commercialisation of Aramchol in Korea
Apricus Biosciences reported on Wednesday that it has received approval from the Republic of Lebanon Ministry of Public Health to market the topical cream Vitaros for the treatment of patients with erectile dysfunction. In addition to the approval, the company has an exclusive license agreement with Elis Pharmaceuticals for the commercialisation of Vitaros in the United Arab Emirates, Oman, Bahrain, Qatar, Saudi Arabia and Kuwait as well as part..."/>
Apricus Biosciences wins Republic of Lebanon Ministry of Public Health approval to market Vitaros for erectile dysfunction
Providence Service Corporation today announced that it is scheduled to report financial results for its second quarter ended June 30, 2016 on Monday, August 1, after the market closes. Providence will hold a conference call at 8:00 a.m. EDT Tuesday, August 2, 2016, to discuss its financial results. Interested parties are invited to listen to the call live over the Internet at http://investor.prscholdings.com."/>
Providence Service Corporation to Report Second Quarter 2016 Results on Monday, August 1st After the Market Closes
Omeros Corporation today announced that it has received scientific advice from the European Medicines Agency in connection with the company's OMS721 Phase 3 program for the treatment of atypical hemolytic uremic syndrome. Based on this EMA advice, the company plans to run the same, single Phase 3 clinical program to support OMS721 marketing approval applications in both the U.S. and in the European Union for the treatment of aHUS."/>
Omeros Corporation Confirms OMS721 Phase 3 Development Plan with European Medicines Agency

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Information Technology856 Articles
Financials849 Articles
Consumer Discretionary726 Articles
Industrials552 Articles
Health Care531 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.